drugset

drugset / Trial / NCT02142634

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

NCT02142634 ↗

Phase 3 Completed 44 enrolled Dr. Falk Pharma GmbH

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.

Timeline

Start: 2014-05
Primary completion: 2020-02
Completion: 2020-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Budesonide	Small molecule	9 mg	—

Indications